With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbioSALT LAKE CITY, Nov. 09, 2023 ...

Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim By David Jagielski – Jun 7, 2024 at 9:00AM ...

The Utah-based pharmaceutical company has trained a large language model to enable scientists to tap into dozens of machine learning models at once, saving them time during drug development.

Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human ...

Recursion plans to utilize this data to train causal AI models to accelerate drug discovery, design biomarkers, and develop patient stratification strategies across a range of disease states.

Shareholders of Recursion and Exscientia have overwhelmingly approved a merger, expected to be finalized on November 20, 2024. This merger aims to combine Recursion’s biological and chemical ...

--The business combination of two AI-powered drug discovery and development companies, Recursion and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion ...

InterviewBit backed tech education startup, Scaler has announced the acquisition of a Delhi-based education platform, Pepcoding, for an undisclosed amount to strengthen Scaler’s business ...

Scaler makes fourth acquisition in 2 years, absorbs Delhi-based Pepcoding Post the transaction, Pepcoding's entire team has merged with Scaler and its co-founder Sumeet Malik has joined the merged ...